Ark-Biodiversity and HTGF have completed the first joint financing round

October 25, 2019

Ark-Biodiversity is the newest foundation of the serial entrepreneur Alexander Olek. The 50-year-old father of four children says:

“I don’t believe in the survival of humanity without biodiversity; and I do not believe in the conservation of biodiversity, unless our societies find joint mechanisms to assign financial value to biodiversity and develop business models that benefit from its preservation. Nobody can address all of the causes of global species extinction, but our technology has the potential to address at least one of them.”

“The global illegal trade in protected and endangered species and the products derived from them is gigantic. With the already existing political and legal frameworks of the Washington and Nagoya agreements supporting us, we could effectively prevent illegal trading of endangered species by consistently applying our innovations.”

Ark-Biodiversity’s business plan is based on a patented technology that makes it possible to generate one standardized complex genetic fingerprint from any higher living being. This genetic pattern is so extensive that, not least, the individual identity of any specimen of any species or product made from it, could be recognized and precisely characterized. This technology has the potential to enable government agencies, non-governmental conservationists, and academic research to address paternity, geographic origin, and other breeding-related, ecological, and academic issues that are critical to curbing illegal trade in protected and threatened species.

The global enforcement of a genetic control system for all transactions involving protected organisms requires additional prerequisites: Although genetic information must be comprehensive, it must be compressed enough to make enormous numbers of analyses affordable. In addition, Ark-Biodiversity’s technology has an inherent genetic address system that is valid for all living beings. Hardly any transaction with a protected or threatened species can be checked for its legality today. The universal genetic address system from Ark-Biodiversity, combined with modern data and transaction technologies such as Blockchain, could process billions of annual transactions with any living creature in a forgery-proof manner and thus give the Washington and Nagoya Accords the teeth they lack so far for effective enforcement.

Following its successful proof-of-concept, the company will begin to attract additional partners, pilot customers and investors to its growth strategy. In particular, Ark-Biodiversity will partner with IT-industry partners specializing in mass transaction processing to provide its genetic information to all stakeholders and carry all transaction of CITES and Nagoya regulated organisms, or products derived from them. Ark-Biodiversity invests the funds raised in the investment round in product and market development in preparation for strategic growth financing.

Tobias Faupel, Senior Investment Manager of High-Tech Gründerfonds (HTGF), comments:

„Ark-Biodiversity’s business model shows that investing in sustainability can also be economically attractive. We are pleased to leverage high-tech for the protection of species together with an equally courageous and experienced founder team.”

About Ark-Biodiversity GmbH
Ark-Biodiversity is a green high-tech company. We make species protection possible by using our many years of scientific know-how, the latest genomic methods and custom adapted big-data technologies. We develop a universal test, the “Universal Fingerprint of Life” with which any living being and its products can be identified and characterized and we use blockchain-based technology, which provides the information gained in a contract- and counterfeit-proof manner for market participant – all for the protection of species and to prevent illegal animal trade.

Ark Biodiversity
Willdenowstraße 6
12203 Berlin
T.: +49 30 3064 4600

About High-Tech Gründerfonds
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 560 startups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry and life sciences.

To date, external investors have injected over EUR 2 billion into the HTGF portfolio via more than 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

High-Tech Gründerfonds Management GmbH
Dr. Bernd Goergen
Schlegelstraße 2
53113 Bonn
T.: +49 228 82300 136

More Press posts

14. October 2021

BASF Venture Capital and Amathaon Capital Acquire Minority Stake in Bioinformatics Company Computomics

Computomics AI recommends crosses adapted to future climatic conditionsPlant breeders can significantly accelerate market launch of new varietiesInvestment promotes innovative solutions for more sustainable agriculture Tübingen, Munich and Ludwigshafen, October 14, 2021 - BASF Venture Capital GmbH (BVC), the corporate venture company of BASF Group, and Amathaon Capital, a venture capital company specializing in AgTech, are investing in the Tübingen-based bioinformatics company Compu
14. October 2021

Abalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 Million

Additional EUR 32.5 million will support clinical readiness and accelerate lead immuno-virotherapy candidates toward clinical proof-of-concept Düsseldorf, Germany, October 14, 2021 – Abalos Therapeutics announced today an extension to its Series A funding round bringing the total raised in this round to EUR 43 million (USD 50 million). The extension was led by Seventure Partners with support from Coparion, Ventura BioMed Investors and Hx Bio Ventures as well as contributions from exist
12. October 2021

STIHL Digital GmbH acquires stake in software startup FlyNex

STIHL has been driving innovation in forestry and gardening for 95 years. To make it easier for customers to work with and in nature, the motor and garden tool manufacturer from Waiblingen near Stuttgart is working intensively on digital technologies. The newly formed partnership between STIHL and FlyNex is intended to support customers in forestry, gardening, and landscaping, particularly with data generated by drones. Hamburg, 10/12/2021 – FlyNex recently closed another financing rou


Notify of
Inline Feedbacks
View all comments